Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05935995
Other study ID # 2023-A00818-37
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 28, 2023
Est. completion date May 2025

Study information

Verified date November 2023
Source Institut de Cancérologie de Lorraine
Contact JEAN LOUIS MERLIN, PharmD, PhD
Phone +33383656062
Email jl.merlin@nancy.unicancer.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Study to evaluate the use of confocal microscopy for detecting resection margins in patients undergoing surgery for basal cell carcinoma of skin and squamous Cell Carcinoma of Head and Neck


Recruitment information / eligibility

Status Recruiting
Enrollment 45
Est. completion date May 2025
Est. primary completion date April 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult patient =18 years old - Squamous cell or basal cell tumor (1 to 4 cm) of mucous or cutaneous origin. - Patient whose surgical indication has been validated in a consultation meeting - Patients with scheduled surgery - WHO< or =2 - ASA < 3 - Patient affiliated to the social security system - Patient has understood, signed and dated the consent form. Exclusion Criteria: - History of irradiation in the surgical area - Women who are pregnant or who are breast-feeding. - Persons deprived of their liberty or under guardianship (including curators)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
microscopy confocal (Histolog Scanner)
Surgical margins of tumor samples will be examined by conventional histopathology (H&E) and confocal microscopy (Histolog® scanner, SamanTree Medical, Switzerland). Depending on the histopathological result obtained between the two methods, the patient may benefit directly from early surgery if the experimental result confirms the presence of positive margins (excluding the learning curve). A learning curve will be established over the first fifteen surgeries, enabling surgical teams to gain experience and systematize specimen flattening. This learning curve will also enable reference images to be produced. The procedure will be carried out by the surgeon and the pathologist in the operating room during this phase.

Locations

Country Name City State
France Gilles Dolivet VandÅ“uvre-lès-Nancy

Sponsors (1)

Lead Sponsor Collaborator
Institut de Cancérologie de Lorraine

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sensitivity and Specificity of Confocal Microscopy Diagnosis Compared to Gold Standard The concordance of intraoperative diagnosis between the two methods will be assessed by the condition of the margins of surgical specimens. Diagnostic accuracy will be measured by the sensitivity and specificity of confocal microscopy, using conventional histology reports from extemporaneous examination as the gold standard.
negative margins (absence of tumour cells) ;
positive margins (presence of tumour cells).
1 day
See also
  Status Clinical Trial Phase
Completed NCT04879849 - A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers Phase 1
Active, not recruiting NCT04474470 - A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer Phase 1/Phase 2
Completed NCT02537223 - Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer Phase 1
Completed NCT00824343 - A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck Cancer Phase 2
Recruiting NCT06022757 - Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) Phase 1/Phase 2
Recruiting NCT05366166 - Pembrolizumab Plus Olaparib in LA-HNSCC Phase 2
Terminated NCT04502888 - Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin Phase 1
Recruiting NCT05007106 - MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) Phase 2
Completed NCT04098458 - Navigation for Timely Adjuvant Therapy for Patients With Locally Advanced HNSCC N/A
Not yet recruiting NCT04528420 - Optimised Early Management of Squamous Cell Carcinoma of the Head and Neck Cancer N/A
Active, not recruiting NCT03997968 - A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05061420 - A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204) Phase 2
Completed NCT04939480 - Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN Phase 2
Recruiting NCT04260802 - A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers Phase 1/Phase 2
Recruiting NCT04465487 - Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies Phase 1
Not yet recruiting NCT05845307 - Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck Early Phase 1
Active, not recruiting NCT04489888 - A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10) Phase 4
Recruiting NCT05544929 - A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers Phase 1
Completed NCT04601402 - GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy Phase 1
Completed NCT00756444 - A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck Phase 2